9
likes
0
comments
daily view 0
monthly view 0
Live Analytics
Comments 0
Episode 3: Building Biotech in a Tough Market | Funding & Cancer Resistance | Anton Xavier Analytics Table
Income Estimates for Episode 3: Building Biotech in a Tough Market | Funding & Cancer Resistance | Anton Xavier
Based on this YouTube video's total view count of 791 views and industry-standard rates, the estimated total earning is $1 - $2 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.
About Episode 3: Building Biotech in a Tough Market | Funding & Cancer Resistance | Anton Xavier
Explore Episode 3: Building Biotech in a Tough Market | Funding & Cancer Resistance | Anton Xavier with 791 views, 9 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.
Episode 3: Building Biotech in a Tough Market | Funding, Cancer Resistance & Entrepreneurship with Anton Xavier What does it really take to build and lead biotech companies in a challenging funding environment? In this episode of Inside the Industry, host Kim Laipple sits down with Anton Xavier, scientist, biotech entrepreneur, venture mentor, and CEO of iNanoRNA Therapeutics and K9 Biotech, for an in-depth conversation about the realities of building early-stage biotech companies. Anton shares lessons from his experience at Pfizer, including how large pharmaceutical companies evaluate scientific opportunities, make difficult go/no-go decisions, manage R&D programs, and determine when a project should be deprioritized or stopped. The conversation explores the challenges facing biotech entrepreneurs today, from venture capital and non-dilutive funding to managing limited resources, team expectations, investor relationships, proof-of-concept data, and the pressure to move programs into the clinic. Anton also discusses his work in human health and animal health, including oncology, infectious disease, and the difficult decision to deprioritize a potential therapeutic approach for African swine fever. He explains how developing therapeutics in animal health can provide valuable proof-of-concept opportunities while creating potential applications across multiple indications. A major focus of the discussion is cancer resistance and tumor heterogeneity. Anton explains why targeting cancer through a single mechanism can lead to treatment resistance and describes the scientific rationale behind a multimodal microRNA approach designed to target multiple mechanisms of cancer biology through a single therapeutic strategy. The conversation also covers the importance of a founder's "why," balancing urgency with scientific rigor, working with clinical investigators, using international clinical development opportunities, and what investors increasingly want to see from early-stage biotech companies. 📙In this episode: ▪️ Building and leading early-stage biotech companies ▪️ Biotech funding and venture capital ▪️ The changing biotech investment environment ▪️ Lessons from Pfizer and big pharma ▪️ Go/no-go decisions in drug development ▪️ Translational science and commercialization ▪️ Cancer resistance and tumor heterogeneity ▪️ Multimodal microRNA therapeutics ▪️ Oncology and infectious disease ▪️ Animal health and human health innovation ▪️ African swine fever and unmet medical needs ▪️ Proof-of-concept studies in animal health ▪️ SBIR and non-dilutive funding ▪️ Clinical PIs and biotech development ▪️ Licensing, M&A and the future of biotech 📙 Hashtags #InsideTheIndustry #KimLaipple #KimberlyLaipple #ScientificSearch #LifeSciences #Biotech #Pharma #Pharmaceutical #HealthcareLeadership #Healthcare #Biotechnology #ClinicalResearch #DrugDevelopment #LifeScience #BiotechLeadership #MedicalInnovation #ExecutiveLeadership #MedTech #MedicalDevices #ExecutiveSearch #Recruiting #Leadership #CareerGrowth #IndustryInsights #Biotech #Biotechnology #LifeSciences #BiotechEntrepreneurship #DrugDevelopment #CancerResearch #CancerResistance #Oncology #BiotechFunding 📙 Keywords Inside the Industry with Kim Laipple, Kim Laipple, Kimberly Laipple, Scientific Search, Life Sciences Podcast, Biotech Podcast, Leadership Podcast,Clinical Research, Drug Development, Healthcare Leadership, Biotech Leadership, Biotech CEO Interview, Anton Xavier, Kim Laipple, biotech entrepreneurship, building a biotech company, early stage biotech, biotech funding, biotech venture capital, cancer resistance, tumor heterogeneity, microRNA therapeutics, oncology drug development, translational science, animal health biotech, African swine fever, iNanoRNA Therapeutics 📙 Connect With Us: ▪️Follow Kimberly Laipple on LinkedIn: https://www.linkedin.com/in/kimberlylaipple/ ▪️Scientific Search on LinkedIn: https://www.linkedin.com/company/scientific-search/ ▪️About Scientific Search: https://scientificsearch.com/ ▪️Follow Scientific Search on Facebook: https://www.facebook.com/scientificsearch/ ▪️Follow Scientific Search on X (Twitter): https://x.com/scientificsch 📙 Connect With the Guest ▪️Follow Anton Xavier on LinkedIn: https://www.linkedin.com/in/anton-xavier-3809b71b/ ▪️K9 Biotech on LinkedIn: https://www.linkedin.com/company/k9-biotech ▪️iNanoRNA Therapeutics on LinkedIn: https://www.linkedin.com/company/inanorna-therapeutics/ 📙 𝐃𝐈𝐒𝐂𝐋𝐀𝐈𝐌𝐄𝐑: The views expressed by guests are their own and are shared for educational and informational purposes only. 📙 𝐂𝐎𝐏𝐘𝐑𝐈𝐆𝐇𝐓 𝐍𝐎𝐓𝐈𝐂𝐄: © Inside the Industry with Kim Laipple. All rights reserved. Unauthorized use, reproduction, or distribution of this content is prohibited. 👋 Thanks for visiting my Channel! 🌟
About YouTube Real-Time View Count
With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.
Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.
Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.
Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.
Embed Widget
Parameters:
fullscreen=true- Fullscreen countergraph=true- Live graph chartcounter=0/1/2- Select counter (0=likes, 1=views, 2=comments)
URL
Click to copy the embed URL to your clipboard

